Common Side Effects of Skyrizi
Skyrizi (risankizumab-rzaa), an IL-23 inhibitor for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, most often causes upper respiratory infections (like colds), headache, fatigue, injection site reactions (redness, pain, or itching), nausea, and fever. These affect 1-10% of patients in clinical trials and are usually mild.[1][2]
Serious Side Effects and Risks
Rare but serious risks include:
- Infections: Increased chance of serious infections like tuberculosis (TB) or fungal infections; screen for TB before starting.[1]
- Hypersensitivity: Allergic reactions such as fainting, swelling of face/lips/tongue, or trouble breathing.[2]
- Liver problems: Elevated liver enzymes, especially with Crohn's; monitor liver function.[1][2]
- Malignancy: Possible higher cancer risk, though data is limited.[1]
Seek immediate medical help for symptoms like persistent fever, cough, weight loss, or yellowing skin.
Side Effects by Condition
- Psoriasis/Psoriatic Arthritis: Upper respiratory infections (14-21%), headache (5%), fatigue (5%), injection reactions (4%).[2]
- Crohn's/UC: Similar profile, plus more nausea (10%) and abdominal pain; liver enzyme rises in up to 3%.[1][2]
How Skyrizi Side Effects Compare to Similar Drugs
Skyrizi has a lower infection rate than TNF inhibitors like Humira (higher serious infections) but similar to other IL-23s like Tremfya. Injection reactions are less frequent than with Stelara.[3] No black box warnings, unlike some biologics.
Who Gets Side Effects and Management Tips
Higher risk in elderly, immunocompromised, or those with infections. Most resolve without stopping treatment. Doctors recommend vaccinations (non-live) before starting, avoiding live vaccines during therapy, and reporting new symptoms promptly.[1][2]
[1]: Skyrizi Prescribing Information (FDA)
[2]: Skyrizi.com Safety Information
[3]: Clinical trial data from Drugs.com and FDA labels